Safety, efficacy and indications of prescription of maraviroc in clinical practice: Factors associated with clinical outcomes.

[1]  V. Calvez,et al.  Antiretroviral-Experienced HIV-1-Infected Patients Treated with Maraviroc: Factors Associated with Virological Response. , 2015, AIDS research and human retroviruses.

[2]  J. Macías,et al.  Efficacy and safety of once‐daily maraviroc plus ritonavir‐boosted darunavir in pretreated HIV‐infected patients in a real‐life setting , 2014, HIV medicine.

[3]  D. Cooper,et al.  Efficacy and safety of maraviroc vs. efavirenz in treatment-naive patients with HIV-1: 5-year findings , 2014, AIDS.

[4]  B. Clotet,et al.  Intensification of a raltegravir-based regimen with maraviroc in early HIV-1 infection , 2014, AIDS.

[5]  M. Nelson,et al.  Five-Year Safety Evaluation of Maraviroc in HIV-1–Infected Treatment-Experienced Patients , 2014, Journal of acquired immune deficiency syndromes.

[6]  D. Kuritzkes,et al.  Virologic Response, Early HIV-1 Decay, and Maraviroc Pharmacokinetics With the Nucleos(t)ide-Free Regimen of MaravIroc Plus Darunavir/Ritonavir in a Pilot Study , 2013, Journal of acquired immune deficiency syndromes.

[7]  A. Lazzarin,et al.  Pharmacokinetics of maraviroc administered at 150 mg once daily in association with lopinavir/ritonavir in HIV-positive treatment-naive patients. , 2013, Journal of Antimicrobial Chemotherapy.

[8]  M. Lederman,et al.  The immunologic effects of maraviroc intensification in treated HIV-infected individuals with incomplete CD4+ T-cell recovery: a randomized trial. , 2013, Blood.

[9]  J. Tilton,et al.  Entry inhibitors and their use in the treatment of HIV-1 infection. , 2013, Antiviral research.

[10]  D. Podzamczer,et al.  Maraviroc Once-Daily Nucleoside Analog-Sparing Regimen in Treatment-Naive Patients: Randomized, Open-Label Pilot Study , 2013, Journal of acquired immune deficiency syndromes.

[11]  P. Harrigan,et al.  Population-Based Sequencing of the V3-loop Can Predict the Virological Response to Maraviroc in Treatment-Naive Patients of the MERIT Trial , 2012, Journal of acquired immune deficiency syndromes.

[12]  Manuel Crespo,et al.  Simplification to dual antiretroviral therapy including a ritonavir-boosted protease inhibitor in treatment-experienced HIV-1-infected patients. , 2012, The Journal of antimicrobial chemotherapy.

[13]  J. Mellors,et al.  A pilot trial of adding maraviroc to suppressive antiretroviral therapy for suboptimal CD4⁺ T-cell recovery despite sustained virologic suppression: ACTG A5256. , 2012, The Journal of infectious diseases.

[14]  R. Paredes,et al.  Update on clinical and methodological recommendations for genotypic determination of HIV tropism to guide the usage of CCR5 antagonists. , 2012, AIDS reviews.

[15]  J. Ainsworth,et al.  Once daily maraviroc 300 mg or 150 mg in combination with ritonavir-boosted darunavir 800/100 mg. , 2012, The Journal of antimicrobial chemotherapy.

[16]  D. Podzamczer,et al.  Dual therapy based on a ritonavir-boosted protease inhibitor as a novel salvage strategy for HIV-1-infected patients on a failing antiretroviral regimen. , 2012, The Journal of antimicrobial chemotherapy.

[17]  L. Vandekerckhove,et al.  Concordance between HIV‐1 genotypic coreceptor tropism predictions based on plasma RNA and proviral DNA , 2011, HIV medicine.

[18]  E. Ribera,et al.  Antiretroviral salvage therapy for multiclass drug-resistant HIV-1-infected patients: from clinical trials to daily clinical practice. , 2011, AIDS reviews.

[19]  A. Wensing,et al.  European guidelines on the clinical management of HIV-1 tropism testing. , 2011, The Lancet. Infectious diseases.

[20]  D. Kuritzkes,et al.  Baseline CD4+ T-cell counts and weighted background susceptibility scores strongly predict response to maraviroc regimens in treatment-experienced patients , 2011, Antiviral therapy.

[21]  B. Clotet,et al.  Efficacy and safety of nucleoside reverse transcriptase inhibitor-sparing salvage therapy for multidrug-resistant HIV-1 infection based on new-class and new-generation antiretrovirals. , 2011, The Journal of antimicrobial chemotherapy.

[22]  L. Stuyver,et al.  Comparison of phenotypic and genotypic tropism determination in triple-class-experienced HIV patients eligible for maraviroc treatment , 2010, The Journal of antimicrobial chemotherapy.

[23]  P. Harrigan,et al.  Population-based V3 genotypic tropism assay: a retrospective analysis using screening samples from the A4001029 and MOTIVATE studies , 2010, AIDS.

[24]  R. Haubrich,et al.  CD4+ T-Cell Restoration After 48 Weeks in the Maraviroc Treatment-Experienced Trials MOTIVATE 1 and 2 , 2010, Journal of acquired immune deficiency syndromes.

[25]  R. Paredes,et al.  Genotypic determination of HIV tropism - clinical and methodological recommendations to guide the therapeutic use of CCR5 antagonists. , 2010, AIDS reviews.

[26]  A. Lazzarin,et al.  Raltegravir, maraviroc, etravirine: an effective protease inhibitor and nucleoside reverse transcriptase inhibitor-sparing regimen for salvage therapy in HIV-infected patients with triple-class experience , 2010, AIDS.

[27]  B. Clotet,et al.  Clinical implications of genotypic resistance to the newer antiretroviral drugs in HIV-1-infected patients with virological failure. , 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[28]  D. Cooper,et al.  Maraviroc versus efavirenz, both in combination with zidovudine-lamivudine, for the treatment of antiretroviral-naive subjects with CCR5-tropic HIV-1 infection. , 2010, The Journal of infectious diseases.

[29]  Amalio Telenti,et al.  Antiretroviral Treatment of Adult HIV Infection2010 Recommendations of the International AIDS Society–USA Panel , 2010 .

[30]  Bernard Hirschel,et al.  Subgroup analyses of maraviroc in previously treated R5 HIV-1 infection. , 2008, The New England journal of medicine.

[31]  Anders Karlsson,et al.  Maraviroc for previously treated patients with R5 HIV-1 infection. , 2008, The New England journal of medicine.

[32]  D. Hazuda,et al.  Raltegravir with optimized background therapy for resistant HIV-1 infection. , 2008, The New England journal of medicine.

[33]  David A. Price,et al.  Maraviroc (UK-427,857), a Potent, Orally Bioavailable, and Selective Small-Molecule Inhibitor of Chemokine Receptor CCR5 with Broad-Spectrum Anti-Human Immunodeficiency Virus Type 1 Activity , 2005, Antimicrobial Agents and Chemotherapy.

[34]  Michael S Saag,et al.  Efficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with HIV-1 , 2005, Nature Medicine.

[35]  A. Mocroft,et al.  Predictors of virological success and ensuing failure in HIV-positive patients starting highly active antiretroviral therapy in Europe: results from the EuroSIDA study. , 2000, Archives of internal medicine.

[36]  J. J. Henning,et al.  Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults and Adolescents, January 28, 2000 , 1998, HIV clinical trials.